Lumos Health opens applications for second cohort of HealthTech and MedTech startups

Healthcare speed-scaling platform offers clinical validation, regulatory support, mentorship, and investor access to startups working across preventive health, oncology, genomics, diagnostics, and digital health

India’s bioeconomy grew 20-fold in last 12 years: Dr Jitendra Singh

From a $10 billion bioeconomy to over $190 billion, indigenous CAR-T therapy, and a booming startup ecosystem highlight 12 years of transformation in India’s science and technology landscape

Orionis expands Novartis partnership in potential $1.4 billion molecular glue drug feal

Lilly’s Jaypirca cuts risk of disease progression or death by 45% in landmark trial

The study enrolled 639 patients, nearly 80% of whom had previously received a covalent BTK inhibitor

Roche wins FDA approval for first PTEN-loss companion diagnostic in prostate cancer

The FDA nod marks a step forward in precision oncology, linking molecular diagnostics more tightly to therapy selection for advanced prostate cancer

OM Pharma to unveil major real-world evidence breakthrough on Broncho-Vaxom at EAACI

The company will unveil preliminary findings showing that Broncho-Vaxom was associated with a 28–38% reduction in respiratory tract infection rates at 12 months

Mabion reactivates MabionCD20 through rare disease collaboration with Oddifact

MabionCD20 is a monoclonal antibody originally developed by Mabion as a biosimilar candidate to MabThera and Rituxan therapies

Granules India elevates Ananda Babu Doppalapudi as GM and Head Quality for Vizag API Unit

Veteran quality professional with over 20 years of industry experience to lead quality operations at Unit-4 API manufacturing facility

Arihant Innochem launches state-of-the-art research & innovation centre in Navi Mumbai

The new facility aims to accelerate formulation science and application-led research across pharma, biopharma, nutraceuticals, personal care, and home care segments

T-CURX gets Swissmedic nod for first human trial of non-viral CAR-T therapy

Phase 1 study to evaluate Siglec-6-targeted CAR-T therapy in relapsed or refractory AML and CLL patients, marking a major milestone for T-CURX’s scalable non-viral CAR-T platform